共 17 条
[1]
The role ofhigh density lipoprotein and liPid-soluable antioxidant vitamins in inhibiting low density liPoprotein oxidation. Mackness MI. Abbott CA,Arrol S,et al. Biochemical Journal . 1 993
[2]
protectiveeffect of HDL associated paraoxonasc inhibition of theological activity of minimally oxidizcd low density lipoprotein. Watson AD Borliner J A Hama SY et al. The Journal of Clinical Investigation . 1995
[3]
Atherosclerosis[P]. DONG CHUNMING;GOLDSCHMIDT PASCAL J.中国专利:US2008095751A1,2008-04-24
[4]
Atherosclerosis[P]. DONG CHUNMING;GOLDSCHMIDT PASCAL J.中国专利:US2008095751A1,2008-04-24
[5]
Role of genet-ic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metaboliteschlorpyrifos paraoxon. Furlong CE,Richter RJ,Seidel SL,et al. The American Journal of Human Genetics . 1988
[6]
Quantitationof human paraoxonase by enzyme-linked immunoassay:population defference in protein concentrations. Blatter MC,Abbott C. Messmer S,et al. Biochemical Journal . 1994
[7]
Distribu-tion of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Mcelveen J,Mackness Ml,Colley CM,et al. Clinical Chemistry . 1986
[8]
Hu-man plasma platele -activating factor acytylhydrolase:oxidatively fragmented phospholipids as substrates. Stremler KE. Stafforini DM. Presott SM,et al. Journal of Biological Chemistry . 1991
[9]
The hunlan serumParaoxonase/arylesteraes polymorphism. Eckerson HW,Wyte CM,La Du BN. The American Journal of Human Genetics . 1983
[10]
Molecular basisfor polymorphic forms of serum paraoxonase/arylesterase.glutamine or arginine at position 191, forthe respective A or B allozymes. Adkins S. Gan KN,Mody M. et al. The American Journal of Human Genetics . 1993